Silexion Therapeutics Corp (SLXN) Reports Annual Financial Results, Focuses on KRAS-Driven Cancer Treatments

Silexion Therapeutics Corp, a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers, released its 10-K filing, detailing its financial performance and operational developments. The company, which was formed through a business combination in August 2024, reported a net loss of $11.9 million for the year ended December 31, 2025, compared to a net loss of $16.5 million for the previous year. The decrease in net loss was primarily attributed to decreases in general and administrative expenses, and financial expenses, including significant decreases in non-cash items related to share-based compensation, and transaction costs related to the Closing of the Business Combination in August 2024, which were not repeated in 2025, as partially offset by an increase in research and development expenses. As of December 31, 2025, Silexion had cash and cash equivalents of $6.0 million.

The company's research and development expenses increased to $7.1 million in 2025 from $5.8 million in 2024, driven by higher subcontractor and consultant costs related to the manufacturing of SIL204, its lead product candidate. General and administrative expenses decreased to $4.5 million from $6.8 million, mainly due to a decrease in non-cash share-based compensation expenses. Silexion has not generated any revenue from product sales to date, and its ability to achieve profitability depends on the successful development and commercialization of its product candidates.

Operationally, Silexion is focused on advancing SIL204, a second-generation siRNA therapeutic, for the treatment of locally advanced pancreatic cancer (LAPC) patients with KRAS mutations. The company held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial, at which BfArM agreed, in principle, to the design. In the fourth quarter of 2025, Silexion submitted an application to the Israeli Ministry of Health for commencing the adaptive Phase 2/3 trial with a safety run-in at several locations in Israel. The company expects to initiate the first part of its Phase 2/3 clinical studies in the second quarter of 2026.

Looking ahead, Silexion plans to submit an application to BfArM to conduct clinical studies in Germany in the first quarter of 2026, and expects to submit applications for trials in additional European Union countries early in 2027. The company also plans to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) in Q1, 2027. Silexion's strategy includes advancing the clinical development of SIL204, leveraging its platform to other oncological indications harboring the KRASG12 mutation, and forming strategic alliances to augment its capabilities. The company's future success depends on its ability to secure additional funding, navigate regulatory approvals, and successfully commercialize its product candidates in a competitive market.

About Silexion Therapeutics Corp

Silexion Therapeutics is a clinical-stage biotech specializing in RNA interference therapies targeting KRAS-driven cancers, notably pancreatic cancer. Its lead candidate, SIL204, aims to silence mutant KRAS genes using intratumoral delivery, with a focus on locally advanced pancreatic tumors. The company develops personalized, targeted treatments to improve survival outcomes, leveraging proprietary technology and strategic collaborations in oncology markets.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.